1 INTRODUCTION
1.1 OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 MARKET SCOPE
1.3 RESEARCH METHODOLOGY
1.3.1 SECONDARY DATA
1.3.2 PRIMARY DATA
1.3.3 MARKET SIZE ESTIMATION
1.3.4 MARKET BREAKDOWN AND DATA TRIANGULATION
1.4 STAKEHOLDERS
1.5 CURRENCY
1.6 RESEARCH ASSUMPTIONS
1.7 LIMITATION
2 EXECUTIVE SUMMARY
3 MARKET OUTLOOK
3.1 INTRODUCTION
3.2 DROC MATRIX
3.3 MARKET CHALLENGES
3.4 MARKET SHARE ANALYSIS
3.5 COST STRUCTURE ANALYSIS
3.6 VALUE CHAIN ANALYSIS
3.7 COVID-19 IMPACT ANALYSES
4 INDUSTRY TRENDS
4.1 INTRODUCTION
4.2 PESTEL ANALYSIS
4.3 PORTER’S FIVE FORCES MODEL
4.3.1 DEGREE OF COMPETITION
4.3.2 BARGAINING POWER OF BUYERS
4.3.3 BARGAINING POWER OF SUPPLIERS
4.3.4 THREAT FROM SUBSTITUTES
4.3.5 THREAT FROM NEW ENTRANTS
5 DRUG REPURPOSING TYPE ANALYSIS
5.1 INTRODUCTION
5.2 HISTORICAL MARKET TYPE ANALYSIS, 2015-2019
5.3 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2020–2030
5.4 Y-O-Y GROWTH TREND ANALYSIS
5.5 ОNСОLОGУ
5.6 СNЅ DІЅЕАЅЕЅ
5.7 NЕURОDЕGЕNЕRАTІVЕ DІЅЕАЅЕЅ
5.8 ОTHЕRЅ
6 DRUG REPURPOSING MARKET APPLICATION ANALYSIS
6.1 INTRODUCTION
6.2 HISTORICAL MARKET APPLICATION ANALYSIS, 2015-2019
6.3 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2020–2030
6.4 Y-O-Y GROWTH TREND ANALYSIS
6.5 НОЅРІTАLЅ
6.6 АMBULАTОRУ ЅURGІСАL СЕNTЕRЅ
6.7 ОTHЕRЅ
7 GLOBAL DRUG REPURPOSING REGIONAL ANALYSIS
7.1 INTRODUCTION
7.2 NORTH AMERICA
7.2.1 NORTH AMERICA HISTORICAL MARKET COUNTRY ANALYSIS, 2015-2019
7.2.2 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2020–2030
7.2.3 Y-O-Y GROWTH TREND ANALYSIS
7.2.3.1 U.S.
7.2.3.2 Canada
7.2.3.3 Mexico
7.3 ASIA-PACIFIC
7.3.1 APAC HISTORICAL MARKET COUNTRY ANALYSIS, 2015-2019
7.3.2 Y-O-Y GROWTH TREND ANALYSIS
7.3.2.1 China
7.3.2.2 Japan
7.3.2.3 Korea
7.3.2.4 India
7.3.2.5 Southeast Asia
7.4 MIDDLE EAST AND AFRICA
7.4.1 MIDDLE EAST AND AFRICA HISTORICAL MARKET COUNTRY ANALYSIS, 2015-2019
7.4.2 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2020–2030
7.4.3 Y-O-Y GROWTH TREND ANALYSIS
7.4.3.1 Saudi Arabia
7.4.3.2 UAE
7.4.3.3 Egypt
7.4.3.4 Nigeria
7.4.3.5 South Africa
7.5 EUROPE
7.5.1 EUROPE HISTORICAL MARKET COUNTRY ANALYSIS, 2015-2019
7.5.2 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2020–2030
7.5.3 Y-O-Y GROWTH TREND ANALYSIS
7.5.3.1 Germany
7.5.3.2 France
7.5.3.3 UK
7.5.3.4 Russia
7.5.3.5 Italy
7.6 SOUTH AMERICA
7.6.1 SOUTH AMERICA HISTORICAL MARKET COUNTRY ANALYSIS, 2015-2019
7.6.2 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2020–2030
7.6.3 Y-O-Y GROWTH TREND ANALYSIS
7.6.3.1 Brazil
7.6.3.2 Argentina
7.6.3.3 Columbia
8 MARKET PLAYERS
8.1 АЅTЕLLАЅ РHАRMА
8.1.1 BUSINESS OVERVIEW:
8.1.2 PRODUCT PORTFOLIO
8.1.3 RECENT DEVELOPMENTS
8.1.4 SWOT ANALYSIS:
8.2 АLLЕRGАN
8.3 ABBVIE INC.
8.4 ACTAVIS INC.
8.5 ALEXION PHARMACEUTICALS INC.
8.6 APOTEX INC.
8.7 AUROBINDO PHARMA LTD.
8.8 BIOGEN IDEC INC.
8.9 BIOVISTA INC.
8.10 CELGENE CORP.
8.11 DR. REDDY'S LABORATORIES LTD.
8.12 ELI LILLY & CO.
8.13 GLAXOSMITHKLINE
8.14 HOFFMANN-LA ROCHE AG
8.15 HOSPIRA INC.
8.16 JENKEN BIOSCIENCES INC.
8.17 JOHNSON & JOHNSON
8.18 MELIOR PHARMACEUTICALS INC
8.19 MERCK & CO. INC.
8.20 MYLAN PHARMACEUTICALS INC.
8.21 NUМЕDІІ
8.22 NOVARTIS AG
8.23 PAR PHARMACEUTICAL INC.
8.24 PFIZER INC.
8.25 SANDOZ
8.26 SANOFI
8.27 SOM BIOTECH SL
8.28 SOSEI GROUP LTD.
8.29 TAKEDA PHARMACEUTICALS U.S.A. INC.
8.30 TEVA PHARMACEUTICAL INDUSTRIES LTD.
8.31 UCB
8.32 ZYDUS CADILA GROUP
9 ABOUT US

TABLE 1 DRUG REPURPOSING REGIONAL ANALYSIS, 2020–2030 (USD MILLION)
TABLE 2 GLOBAL DRUG REPURPOSING MARKET, 2020–2030, (USD MILLION)
TABLE 3 DRUG REPURPOSING CURRENT AND FUTURE REGIONAL ANALYSIS, 2020–2030 (USD MILLION)
TABLE 4 GLOBAL DRUG REPURPOSING HISTORICAL MARKET TYPE ANALYSIS, 2015-2019, (USD MILLION)
TABLE 5 DRUG REPURPOSING CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030 (USD MILLION)
TABLE 6 GLOBAL DRUG REPURPOSING HISTORICAL MARKET APPLICATION ANALYSIS, 2015-2019, (USD MILLION)
TABLE 7 DRUG REPURPOSING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030 (USD MILLION)
TABLE 8 NORTH AMERICA DRUG REPURPOSING HISTORICAL MARKET ANALYSIS, 2015-2019, (USD MILLION)
TABLE 9 NORTH AMERICA DRUG REPURPOSING CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030 (USD MILLION)
TABLE 10 NORTH AMERICA DRUG REPURPOSING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030 (USD MILLION)
TABLE 11 U.S. DRUG REPURPOSING CURRENT AND FUTURE TYPE ANALYSIS, 2015–2020
TABLE 12 U.S. DRUG REPURPOSING CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 13 U.S. DRUG REPURPOSING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 14 CANADA DRUG REPURPOSING CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 15 CANADA DRUG REPURPOSING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 16 MEXICO DRUG REPURPOSING CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 17 MEXICO DRUG REPURPOSING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 18 APAC DRUG REPURPOSING HISTORICAL MARKET ANALYSIS, 2015-2019, (USD MILLION)
TABLE 19 ASIA-PACIFIC DRUG REPURPOSING CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030 (USD MILLION)
TABLE 20 ASIA-PACIFIC DRUG REPURPOSING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030 (USD MILLION)
TABLE 21 CHINA DRUG REPURPOSING CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 22 CHINA DRUG REPURPOSING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 23 JAPAN DRUG REPURPOSING CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 24 JAPAN DRUG REPURPOSING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 25 KOREA DRUG REPURPOSING CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 26 KOREA DRUG REPURPOSING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 27 INDIA DRUG REPURPOSING CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 28 INDIA DRUG REPURPOSING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 29 SOUTHEAST ASIA DRUG REPURPOSING CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 30 SOUTHEAST ASIA DRUG REPURPOSING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 31 MIDDLE EAST AND AFRICA DRUG REPURPOSING HISTORICAL MARKET ANALYSIS, 2015-2019, (USD MILLION)
TABLE 32 MIDDLE EAST AND AFRICA DRUG REPURPOSING CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030 (USD MILLION)
TABLE 33 MIDDLE EAST AND AFRICA DRUG REPURPOSING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030 (USD MILLION)
TABLE 34 SAUDI ARABIA DRUG REPURPOSING CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 35 SAUDI ARABIA DRUG REPURPOSING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 36 UAE DRUG REPURPOSING CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 37 UAE DRUG REPURPOSING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 38 EGYPT DRUG REPURPOSING CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 39 EGYPT DRUG REPURPOSING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 40 NIGERIA DRUG REPURPOSING CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 41 NIGERIA DRUG REPURPOSING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 42 SOUTH AFRICA DRUG REPURPOSING CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 43 SOUTH AFRICA DRUG REPURPOSING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 44 EUROPE DRUG REPURPOSING HISTORICAL MARKET ANALYSIS, 2015-2019, (USD MILLION)
TABLE 45 EUROPE DRUG REPURPOSING CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030 (USD MILLION)
TABLE 46 EUROPE DRUG REPURPOSING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030 (USD MILLION)
TABLE 47 GERMANY DRUG REPURPOSING CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 48 GERMANY DRUG REPURPOSING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 49 FRANCE DRUG REPURPOSING CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 50 FRANCE DRUG REPURPOSING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 51 UK DRUG REPURPOSING CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 52 UK DRUG REPURPOSING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 53 RUSSIA DRUG REPURPOSING CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 54 RUSSIA DRUG REPURPOSING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 55 ITALY DRUG REPURPOSING CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 56 ITALY DRUG REPURPOSING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 57 SOUTH AMERICA DRUG REPURPOSING HISTORICAL MARKET ANALYSIS, 2015-2019, (USD MILLION)
TABLE 58 SOUTH AMERICA DRUG REPURPOSING CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030 (USD MILLION)
TABLE 59 SOUTH AMERICA DRUG REPURPOSING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030 (USD MILLION)
TABLE 60 BRAZIL DRUG REPURPOSING CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 61 BRAZIL DRUG REPURPOSING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 62 ARGENTINA DRUG REPURPOSING CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 63 ARGENTINA DRUG REPURPOSING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 64 COLUMBIA DRUG REPURPOSING CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 65 COLUMBIA DRUG REPURPOSING CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)